Celldex Therapeutics, Inc. (CLDX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Celldex Therapeutics, Inc. reported revenue of $1.54M, down 78.0% from the prior year. The company ran a net loss, with a net margin of -16748.0%. It held $582.98M in total assets against $55.82M in total liabilities.
Key ratios (FY2025)
-18599.8%
Operating margin
-16748.0%
Net margin
-49.1%
Return on equity
-78.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.54M | $7.02M | $6.88M | $2.36M | $4.65M | $7.42M | $3.57M | $9.54M | $12.74M | $6.79M |
| Cost of Revenue | $200.0K | $200.0K | $300.0K | $100.0K | $100.0K | $200.0K | $100.0K | $700.0K | $700.0K | $1.60M |
| Operating Income | -$287.37M | -$195.08M | -$154.54M | -$115.23M | -$71.24M | -$63.35M | -$55.03M | -$156.44M | -$121.53M | -$132.92M |
| Net Income | -$258.76M | -$157.86M | -$141.43M | — | — | — | — | — | — | — |
| EPS (Diluted) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 | $-2.02 | $-3.51 | — | — | — |
| Total Assets | $582.98M | $792.34M | $465.63M | $352.74M | $444.65M | $235.84M | $122.93M | $155.81M | $315.62M | $383.36M |
| Total Liabilities | $55.82M | $45.34M | $36.46M | $26.53M | $25.18M | $26.48M | $28.91M | $31.75M | $79.25M | $117.93M |
| Shareholders' Equity | $527.16M | $747.00M | $429.17M | $326.20M | $419.48M | $209.36M | $94.03M | $124.06M | $236.37M | $265.43M |
| Cash & Equivalents | $28.87M | $28.36M | $34.81M | $29.43M | $39.14M | $43.84M | $11.23M | $24.31M | $40.29M | $42.46M |
| Operating Cash Flow | -$210.94M | -$157.78M | -$107.29M | -$103.73M | -$60.91M | -$40.40M | -$46.41M | -$75.23M | -$99.93M | -$113.04M |
| Capital Expenditures | $2.71M | $1.92M | $1.82M | $1.83M | $1.25M | $1.55M | $731.0K | $813.0K | $1.79M | $2.75M |
| Shares Outstanding | 66.55M | 66.37M | 55.88M | 47.20M | 46.73M | 39.60M | 16.97M | 11.96M | 9.23M | 120.52M |